Evidence map›Paper›PMID 25122785›Full record

ArticleJournal of virology2014

Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies.

Claire Vandergeeten, Rémi Fromentin, Esther Merlini, Mariam B Lawani, Sandrina DaFonseca, Wendy Bakeman, Amanda McNulty, Moti Ramgopal, Nelson Michael, Jerome H Kim and 2 more

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 227 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. HCV-specific CD4EBioMedicine · 2026
    Article
  7. Article
  8. Dual CD8 and TCR editing in regulatory T cells mediates HLA-A2-restricted tissue-specific homing.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  9. Article
  10. Targeting PD-1Science advances · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Activation of CXCR3Journal of virology · 2025
    Article
  19. Article
  20. Article

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Claire VandergeetenVaccine and Gene Therapy Institute Florida, Port St. Lucie, Florida, USA.
Rémi FromentinVaccine and Gene Therapy Institute Florida, Port St. Lucie, Florida, USA.
Esther MerliniUniversity of Milan, Clinic of Infectious Diseases, Department of Health Sciences, Milan, Italy.
Mariam B LawaniVaccine and Gene Therapy Institute Florida, Port St. Lucie, Florida, USA.
Sandrina DaFonsecaVaccine and Gene Therapy Institute Florida, Port St. Lucie, Florida, USA.
Wendy BakemanVaccine and Gene Therapy Institute Florida, Port St. Lucie, Florida, USA.
Amanda McNultyVaccine and Gene Therapy Institute Florida, Port St. Lucie, Florida, USA.
Moti RamgopalMidway Immunology & Research Center, Fort Pierce, Florida, USA.
Nelson MichaelUnited States Military HIV Research Program, Silver Spring, Maryland, USA.
Jerome H KimUnited States Military HIV Research Program, Silver Spring, Maryland, USA.
Jintanat AnanworanichUnited States Military HIV Research Program, Silver Spring, Maryland, USA Thai Red Cross AIDS Research Centre, Pathumwan, Bangkok, Thailand.
Nicolas ChomontVaccine and Gene Therapy Institute Florida, Port St. Lucie, Florida, USA nchomont@vgtifl.org.
Vaccine & Gene Therapy Institute of Florida · USMidway College · USThai Red Cross Society · THUniversity of Milan · IT

Funding

Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2011 to 2015
$29.5M
TILDA: A new sensitive and precise assay to measure the size of the latent HIV reservoirR21AI113096 · NIAID · VGTI FLORIDA · PI CHOMONT, NICOLAS · 2014 to 2015
$334k
NIAID NIH HHS 1R21AI113096NIAID NIH HHS 1U19AI096109NIAID NIH HHS R21 AI113096NIAID NIH HHS U19 AI096109
6 · The paper itself

Abstract

unlabelledA small pool of infected cells persists in HIV-infected individuals receiving antiretroviral therapy (ART). Here, we developed ultrasensitive assays to precisely measure the frequency of cells harboring total HIV DNA, integrated HIV DNA, and two long terminal repeat (2-LTR) circles. These assays are performed on cell lysates, which circumvents the labor-intensive step of DNA extraction, and rely on the coquantification of each HIV molecular form together with CD3 gene sequences to precisely measure cell input. Using primary isolates from HIV subtypes A, B, C, D, and CRF01_A/E, we demonstrate that these assays can efficiently quantify low target copy numbers from diverse HIV subtypes. We further used these assays to measure total HIV DNA, integrated HIV DNA, and 2-LTR circles in CD4(+) T cells from HIV-infected subjects infected with subtype B. All samples obtained from ART-naive subjects were positive for the three HIV molecular forms (n = 15). Total HIV DNA, integrated HIV DNA, and 2-LTR circles were detected in, respectively, 100%, 94%, and 77% of the samples from individuals in which HIV was suppressed by ART. Higher levels of total HIV DNA and 2-LTR circles were detected in untreated subjects than individuals on ART (P = 0.0003 and P = 0.0004, respectively), while the frequency of CD4(+) T cells harboring integrated HIV DNA did not differ between the two groups. These results demonstrate that these novel assays have the ability to quantify very low levels of HIV DNA of multiple HIV subtypes without the need for nucleic acid extraction, making them well suited for the monitoring of viral persistence in large populations of HIV-infected individuals. IMPORTANCE: Since the discovery of viral reservoirs in HIV-infected subjects receiving suppressive ART, measuring the degree of viral persistence has been one of the greatest challenges in the field of HIV research. Here, we report the development and validation of ultrasensitive assays to measure HIV persistence in HIV-infected individuals from multiple geographical regions. These assays are relatively inexpensive, do not require DNA extraction, and can be completed in a single day. Therefore, they are perfectly adapted to monitor HIV persistence in large cohorts of HIV-infected individuals and, given their sensitivity, can be used to monitor the efficacy of therapeutic strategies aimed at interfering with HIV persistence after prolonged ART.

Indexed as

Cohort StudiesDNA, ViralHIVHIV InfectionsHumansPolymerase Chain ReactionSensitivity and SpecificityViral LoadDNA, Viral

Identifiers

PMID25122785
PMCPMC4248919
OpenAlexW2154138428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.